Railway Pension Investments Ltd decreased its position in Amgen Inc. (NASDAQ:AMGN – Free Report) by 8.0% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 342,206 shares of the medical research company’s stock after selling 29,800 shares during the quarter. Railway Pension Investments Ltd owned approximately 0.06% of Amgen worth $97,296,000 as of its most recent SEC filing.
Other institutional investors also recently modified their holdings of the company. BIP Wealth LLC boosted its stake in Amgen by 2.6% in the fourth quarter. BIP Wealth LLC now owns 1,249 shares of the medical research company’s stock valued at $360,000 after buying an additional 32 shares in the last quarter. RFP Financial Group LLC raised its position in shares of Amgen by 17.1% during the first quarter. RFP Financial Group LLC now owns 219 shares of the medical research company’s stock worth $62,000 after acquiring an additional 32 shares during the last quarter. Marino Stram & Associates LLC raised its position in shares of Amgen by 0.7% during the fourth quarter. Marino Stram & Associates LLC now owns 4,626 shares of the medical research company’s stock worth $1,332,000 after acquiring an additional 34 shares during the last quarter. NTV Asset Management LLC raised its position in shares of Amgen by 0.3% during the first quarter. NTV Asset Management LLC now owns 10,961 shares of the medical research company’s stock worth $3,116,000 after acquiring an additional 34 shares during the last quarter. Finally, Texas Yale Capital Corp. raised its position in shares of Amgen by 0.3% during the first quarter. Texas Yale Capital Corp. now owns 10,097 shares of the medical research company’s stock worth $2,871,000 after acquiring an additional 34 shares during the last quarter. Institutional investors own 76.50% of the company’s stock.
Amgen Stock Performance
Shares of NASDAQ AMGN traded down $1.54 during trading on Friday, reaching $333.99. 2,106,216 shares of the stock traded hands, compared to its average volume of 1,890,833. Amgen Inc. has a 52-week low of $228.21 and a 52-week high of $346.85. The company has a debt-to-equity ratio of 11.96, a current ratio of 1.42 and a quick ratio of 0.98. The company has a 50-day moving average of $316.30 and a 200-day moving average of $298.33. The stock has a market capitalization of $179.16 billion, a P/E ratio of 47.71, a price-to-earnings-growth ratio of 2.78 and a beta of 0.58.
Amgen Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Tuesday, August 6th. Stockholders of record on Friday, August 16th will be given a dividend of $2.25 per share. This represents a $9.00 dividend on an annualized basis and a dividend yield of 2.69%. Amgen’s dividend payout ratio is presently 128.57%.
Analysts Set New Price Targets
A number of equities analysts have recently issued reports on AMGN shares. TD Cowen lowered their price objective on Amgen from $370.00 to $360.00 and set a “buy” rating for the company in a research report on Wednesday, April 17th. Truist Financial reiterated a “buy” rating and issued a $320.00 target price on shares of Amgen in a report on Friday, April 12th. Barclays upgraded Amgen from an “underweight” rating to an “equal weight” rating and lifted their target price for the stock from $230.00 to $300.00 in a report on Friday, May 3rd. Royal Bank of Canada lifted their target price on Amgen from $328.00 to $332.00 and gave the stock an “outperform” rating in a report on Friday, June 14th. Finally, William Blair upgraded Amgen from a “market perform” rating to an “outperform” rating in a report on Friday, May 3rd. Ten equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $312.63.
Get Our Latest Stock Report on AMGN
Amgen Company Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
See Also
- Five stocks we like better than Amgen
- Conference Calls and Individual Investors
- Hims & Hers Stock Falls on DexCom Fears: Analysts Predict Rally
- Bank Stocks – Best Bank Stocks to Invest In
- Snap’s Stock Plummets on Q2 Revenue Guidance Shortfall
- How to Read Stock Charts for Beginners
- Intel Loses a Quarter of Its Value After Horrible Earnings Report
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.